bluuebunny/crossref_metadata_2025_split huggingface dataset:
Public service values and e-administration: an explosive mix? Illustration drawing on the case of the Family Allowance Funds (Caisses d’Allocations Familiales) in France
Authors: Roux Laetitia 
Published: January 2015

Despite the fact that Information and Communication Technologies (ICTs) are considered to be an important state modernization tool, resistance to change can sometimes be observed. The question is why? On the basis of intervention research mobilizing five different corpuses of material over eight years in the family branch of the French social security system, we have established that values can be an (accelerating or blocking) structuring element of an ambiguous e-administration development dynamic. In other words, in the process of enacting or activating technologies intended to modernize public services, sensemaking by managers faced with the conflicts of values generated or exacerbated by the introduction of these new management tools is fundamental to understanding the process of change. Based on this research result, recommendations for action have been drawn up for the managers, the aim being to elucidate these value conflicts within discussion forums, even if this implies a certain cost. Points for practitioners This article shows that the e-administration development dynamics depend in part on sensemaking by public service managers around technologies. Indeed, these technologies exacerbate or introduce conflicts of values. Interactivity (a property inherent to ICT that must be respected for the sake of the value of public service adaptability), in particular, may conflict with the value of public sector equality. This is at least what we have observed in the course of the research conducted for nearly eight years in the family branch of the French social security system. This therefore raises questions about the effectiveness of elucidating these value conflicts within discussion forums to facilitate the development of e-administration.
Attenuation of Streptomycin Ototoxicity by Tetramethylpyrazine in Guinea Pig Cochlea
Authors: Cui Cheng , Liu Dajun , Qin Xin 
Published: January 2015

ObjectiveTetramethylpyrazine has been suggested to have a therapeutic effect on impaired hearing that is induced by aminoglycoside antibiotics. However, its effectiveness on streptomycin ototoxicity and its cellular mechanisms are relatively unknown. Here we investigate the protective effect of tetramethylpyrazine on streptomycin‐induced ototoxicity in guinea pig cochlea.Study DesignProspective randomized laboratory study.SettingHearing Research Laboratory of China Medical University.Subjects and MethodsAdult guinea pigs were randomized to 4 groups. Hearing sensitivity of guinea pigs was tested by auditory brainstem response measurements before streptomycin exposure and again 10 days later. The cochlear tissues were prepared for electron microscopy and immunohistochemical staining of heat shock protein 70 (HSP70). The effect of tetramethylpyrazine on streptomycin‐induced activation of caspase‐3 was evaluated by Western blotting.ResultsCo‐therapy with tetramethylpyrazine reduced a profound streptomycin‐induced auditory threshold shift compared with streptomycin treatment alone (P =. 0002 or P =. 00008). Tetramethylpyrazine also attenuated the structural disruption in streptomycin‐treated outer hair cells and marginal cells of vascular stria by transmission electronic microscopy and scanning electronic microscopy, respectively. Moreover, tetramethylpyrazine decreased the streptomycin‐stimulated expressions of HSP70 and caspase‐3. The correlation analysis demonstrated that HSP70 expression had a positive correlation with auditory brainstem response thresholds (|R| = 0.6‐0.9, P =. 0073 or P =. 0169).ConclusionsOur data suggest that the protective effect of tetramethylpyrazine on hearing function is associated with the reduction of stress response and inhibition of apoptosis. Tetramethylpyrazine may have therapeutic potential for patients with ototoxicity diseases.
Esophageal Visualization as an Adjunct to the Videofluoroscopic Study of Swallowing
Authors: Miles Anna , McMillan Jessica , Ward Katie , Allen Jacqui 
Published: January 2015

ObjectiveComplaints of dysphagia for solids lead to speech‐language pathology (SLP) referral. Yet many of these patients are later diagnosed with esophageal rather than oropharyngeal dysphagia. Fluoroscopic screening involving the oropharynx alone fails to identify these patients. The aim of this study was to investigate the prevalence of esophageal abnormalities in an SLP‐led videofluoroscopic study of swallowing (VFSS) clinic.Study DesignProspective, observational study.SettingRadiology suite, public hospital.Subjects and MethodsIn total, 111 consecutive mixed‐etiology patients referred to the clinic by otorhinolaryngology (ORL) (59) or by a speech‐language pathologist (52) were recruited. A VFSS was performed according to protocol, and at completion, esophageal visualization (in anterior‐posterior plane) was performed by administration of a large liquid barium bolus and a barium capsule. All VFSS recordings were analyzed using objective digital measures of timing and displacement.ResultsSixty‐eight percent of patients had an abnormal esophageal transit. One‐third of those referred presented exclusively with esophageal abnormalities, while one‐third had both oropharyngeal and esophageal abnormalities. Oral abnormalities, reduced pharyngoesophageal segment maximum opening (PESmax), and increasing age were significantly associated with esophageal abnormalities.ConclusionFluoroscopic evaluation of the pharynx alone, without esophageal review, risks incomplete diagnosis of patients with esophageal disorders. Using esophageal visualization allows timely referral for further investigation by appropriate medical specialties, avoiding incomplete management of patients with dysphagia.
228 Cases of Cochlear Implant Receiver‐Stimulator Placement in a Tight Subperiosteal Pocket without Fixation
Authors: Sweeney Alex D. , Carlson Matthew L. , Valenzuela Carla V. , Wanna George B. , Rivas Alejandro , Bennett Marc L. , Haynes David S. 
Published: January 2015

Objectives(1) To investigate the outcomes of cochlear implant receiver‐stimulator (RS) placement using a tight subperiosteal pocket technique without device fixation and (2) to compare the efficiency of this approach with the traditional bony well and trough technique.Study DesignCase series with planned chart review.SettingSingle tertiary academic referral center.Subjects and MethodsAll cochlear implant surgeries utilizing a tight subperiosteal pocket without additional fixation or use of a bone well were identified retrospectively. Revision cases were only included if the tight subperiosteal pocket technique was used during the initial surgery. Patients with less than 6 months of postoperative follow‐up were excluded. Primary outcome measures included RS migration, flap complications, device failure, and percentage reduction in operative time.ResultsTwo hundred twenty‐eight cases (average age 45.3 years) met inclusion criterion and were analyzed. At a mean follow‐up of 18.1 months, no patient experienced RS migration. One patient experienced a postoperative hematoma that was managed with observation. One patient developed a surgical site infection that resolved following exploration and intravenous antibiotics. The subperiosteal pocket technique resulted in an 18.9% reduction in total operative time compared to a more conventional RS placement method (P <. 01).ConclusionsThe tight subperiosteal pocket without fixation is a safe, durable, and time‐saving technique for RS placement during cochlear implantation. Notably, device migration and flap complications are very uncommon.
Arthroscopic Ankle Fusion for Avascular Necrosis of the Talus
Authors: Kendal Adrian R. , Cooke Paul , Sharp Robert 
Published: January 2015

Background: Avascular necrosis (AVN) of the talus is a painful condition leading to destruction of the ankle-hindfoot complex. Moderate outcomes and high complication rates are reported in small numbers of advanced disease treated with tibiotalocalcaneal fusion, which has the additional disadvantage of sacrificing both the ankle and subtalar joints. The blood supply of the talus is tenuous, and open procedures risk further talar collapse by disrupting extraosseous vessels. This article reports the outcome of arthroscopic ankle fusion for late-stage AVN of the talus. Our hypothesis was that arthroscopic ankle fusion would relieve symptoms of advanced talar AVN, prevent collapse of the talus, and preserve the subtalar joint. Methods: A cohort study was performed on 16 patients with talar AVN treated with arthroscopic ankle fusion. Our primary outcome was fusion rate. Secondary outcomes included perioperative complications, ongoing pain, and further operative intervention. All radiologic investigations were reported independently by a senior radiologist. The average age of the patients was 53.5 years. The presumed causes of talar AVN were steroids, trauma, hematologic disorders, and alcoholism. The etiology was unknown in 7 patients. One patient was lost to follow-up. Results: Clinical and radiologic fusion at the ankle joint was confirmed in 15 of 15 available patients. Thirteen patients reported resolution of pain at follow-up. Three patients had ongoing pain and underwent a subsequent successful subtalar fusion. Conclusions: Arthroscopic ankle fusion was a safe and reliable treatment of symptomatic advanced talar AVN. It was a minimally invasive procedure with minimal complication rate, preserving the talus and sparing the subtalar joint. Level of Evidence: Level IV, retrospective case series.
MOZ regulates B-cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development
Authors: Sheikh Bilal N. , Lee Stanley C. W. , El-Saafin Farrah , Vanyai Hannah K. , Hu Yifang , Pang Swee Heng Milon , Grabow Stephanie , Strasser Andreas , Nutt Stephen L. , Alexander Warren S. , Smyth Gordon K. , Voss Anne K. , Thomas Tim 
Published: January 2015

Key Points
Regulation of genes required for B-cell progenitor proliferation is exquisitely dependent on Moz gene dosage. Loss of one Moz allele delays the onset of MYC-driven lymphoma by 3.9-fold.
Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma
Authors: Duvic Madeleine , Pinter-Brown Lauren C. , Foss Francine M. , Sokol Lubomir , Jorgensen Jeffrey L. , Challagundla Pramoda , Dwyer Karen M. , Zhang Xiaoping , Kurman Michael R. , Ballerini Rocco , Liu Li , Kim Youn H. 
Published: January 2015

Key Points
Mogamulizumab was well-tolerated in 41 patients with previously treated mycosis fungoides or Sézary syndrome. Durable responses observed with a global overall response rate of 36.8%; patients with Sézary syndrome had a response rate of 47.1%.
High electron mobility and low carrier concentration of hydrothermally grown ZnO thin films on seeded a-plane sapphire at low temperature
Authors: Jayah Nurul Azzyaty , Yahaya Hafizal , Mahmood Mohamad Rusop , Terasako Tomoaki , Yasui Kanji , Hashim Abdul Manaf 
Published: January 2015

Abstract
Hydrothermal zinc oxide (ZnO) thick films were successfully grown on the chemical vapor deposition (CVD)-grown thick ZnO seed layers on a-plane sapphire substrates using the aqueous solution of zinc nitrate dehydrate (Zn(NO3)2). The use of the CVD ZnO seed layers with the flat surfaces seems to be a key technique for obtaining thick films instead of vertically aligned nanostructures as reported in many literatures. All the hydrothermal ZnO layers showed the large grains with hexagonal end facets and were highly oriented towards the c-axis direction. Photoluminescence (PL) spectra of the hydrothermal layers were composed of the ultraviolet (UV) emission (370 to 380 nm) and the visible emission (481 to 491 nm), and the intensity ratio of the former emission (I
UV) to the latter emission (I
VIS) changed, depending on both the molarity of the solution and temperature. It is surprising that all the Hall mobilities for the hydrothermal ZnO layers were significantly larger than those for their corresponding CVD seed films. It was also found that, for the hydrothermal films grown at 70°C to 90°C, the molarity dependences of I
UV/I
VIS resembled those of mobilities, implying that the mobility in the film is affected by the structural defects. The highest mobility of 166 cm2/Vs was achieved on the hydrothermal film with the carrier concentration of 1.65 × 1017 cm−3 grown from the aqueous solution of 40 mM at 70°C.
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
Authors: Teulings Hansje-Eva , Limpens Jacqueline , Jansen Sophia N. , Zwinderman Aeilko H. , Reitsma Johannes B. , Spuls Phyllis I. , Luiten Rosalie M. 
Published: January 2015

Purpose Vitiligo-like depigmentation in patients with melanoma may be associated with more favorable clinical outcome. We conducted a systematic review of patients with stage III to IV melanoma treated with immunotherapy to determine the cumulative incidence of vitiligo-like depigmentation and the prognostic value of vitiligo development on survival. Methods We systemically searched and selected all studies on melanoma immunotherapy that reported on autoimmune toxicity and/or vitiligo between 1995 and 2013. Methodologic quality of each study was appraised using adapted criteria for systematic reviews in prognostic studies. Random-effect models were used to calculate summary estimates of the cumulative incidence of vitiligo-like depigmentation across studies. The prognostic value of vitiligo-like depigmentation on survival outcome was assessed using random-effects Cox regression survival analyses. Results One hundred thirty-seven studies were identified comprising 139 treatment arms (11 general immune stimulation, 84 vaccine, 28 antibody-based, and 16 adoptive transfer) including a total of 5,737 patients. The overall cumulative incidence of vitiligo was 3.4% (95% CI, 2.5% to 4.5%). In 27 studies reporting individual patient data, vitiligo development was significantly associated with both progression-free-survival (hazard ratio [HR], 0.51; 95% CI, 0.32 to 0.82; P < .005) and overall survival (HR, 0.25; 95% CI, 0.10 to 0.61; P < .003), indicating that these patients have two to four times less risk of disease progression and death, respectively, compared with patients without vitiligo development. Conclusion Although vitiligo occurs only in a low percentage of patients with melanoma treated with immunotherapy, our findings suggest clear survival benefit in these patients. Awareness of vitiligo induction in patients with melanoma is important as an indicator of robust antimelanoma immunity and associated improved survival
KIT and PDGFRA Mutations and the Risk of GI Stromal Tumor Recurrence
Authors: Joensuu Heikki , Rutkowski Piotr , Nishida Toshirou , Steigen Sonja E. , Brabec Peter , Plank Lukas , Nilsson Bengt , Braconi Chiara , Bordoni Andrea , Magnusson Magnus K. , Sufliarsky Jozef , Federico Massimo , Jonasson Jon G. , Hostein Isabelle , Bringuier Pierre-Paul , Emile Jean-Francois 
Published: January 2015

Purpose Mutated KIT and platelet-derived growth factor alpha gene (PDGFRA) drive GI stromal tumor (GIST) oncogenesis, but the clinical significance of their single mutations is known incompletely. Patients and Methods We identified 11 population-based series of patients with GIST through a literature search and pooled individual data from 3,067 patients treated with macroscopically complete tumor excision. Mutation analysis was done from 1,505 tumors. We analyzed associations between KIT and PDGFRA mutations and recurrence-free survival (RFS) in the subsets in which patients were treated with surgery alone. Results We identified 301 different single mutations in KIT and 33 in PDGFRA. Patients with PDGFRA mutations had more favorable RFS than those with KIT mutations (hazard ratio, 0.34; P = .004). Only one of the 35 GISTs with KIT exon 11 duplication mutations recurred. Patients with deletions of only one codon of KIT exon 11 had better RFS than those with another deletion type, and some KIT exon 11 substitution mutations (Trp557Arg, Val559Ala, and Leu576Pro) were also associated with favorable RFS. Patients with an identical mutation had greatly variable outcomes depending on the standard prognostic factors, notably, mitotic count. Commonly used risk stratification schemes tended to overestimate the risk for recurrence in subgroups with prognostically favorable mutations. Conclusion GISTs with an identical KIT or PDGFRA mutation may have widely varying risks for recurrence. Most of the patients with PDGFRA mutations and those with KIT exon 11 duplication mutation or deletion of one codon have favorable RFS with surgery alone and are usually not candidates for adjuvant therapy.
Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement
Authors: Dimopoulos Meletios A. , Hillengass Jens , Usmani Saad , Zamagni Elena , Lentzsch Suzanne , Davies Faith E. , Raje Noopur , Sezer Orhan , Zweegman Sonja , Shah Jatin , Badros Ashraf , Shimizu Kazuyuki , Moreau Philippe , Chim Chor-Sang , Lahuerta Juan José , Hou Jian , Jurczyszyn Artur , Goldschmidt Hartmut , Sonneveld Pieter , Palumbo Antonio , Ludwig Heinz , Cavo Michele , Barlogie Bart , Anderson Kenneth , Roodman G. David , Rajkumar S. Vincent , Durie Brian G.M. , Terpos Evangelos 
Published: January 2015

Purpose The aim of International Myeloma Working Group was to develop practical recommendations for the use of magnetic resonance imaging (MRI) in multiple myeloma (MM). Methods An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations for the value of MRI based on data published through March 2014. Recommendations MRI has high sensitivity for the early detection of marrow infiltration by myeloma cells compared with other radiographic methods. Thus, MRI detects bone involvement in patients with myeloma much earlier than the myeloma-related bone destruction, with no radiation exposure. It is the gold standard for the imaging of axial skeleton, for the evaluation of painful lesions, and for distinguishing benign versus malignant osteoporotic vertebral fractures. MRI has the ability to detect spinal cord or nerve compression and presence of soft tissue masses, and it is recommended for the workup of solitary bone plasmacytoma. Regarding smoldering or asymptomatic myeloma, all patients should undergo whole-body MRI (WB-MRI; or spine and pelvic MRI if WB-MRI is not available), and if they have > one focal lesion of a diameter > 5 mm, they should be considered to have symptomatic disease that requires therapy. In cases of equivocal small lesions, a second MRI should be performed after 3 to 6 months, and if there is progression on MRI, the patient should be treated as having symptomatic myeloma. MRI at diagnosis of symptomatic patients and after treatment (mainly after autologous stem-cell transplantation) provides prognostic information; however, to date, this does not change treatment selection.
Monitoring of Minimal Residual Disease After Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the ALL-BFM-SCT 2003 Trial
Authors: Bader Peter , Kreyenberg Hermann , von Stackelberg Arend , Eckert Cornelia , Salzmann-Manrique Emilia , Meisel Roland , Poetschger Ulrike , Stachel Daniel , Schrappe Martin , Alten Julia , Schrauder Andre , Schulz Ansgar , Lang Peter , Müller Ingo , Albert Michael H. , Willasch Andre M. , Klingebiel Thomas E. , Peters Christina 
Published: January 2015

PurposeTo elucidate the impact of minimal residual disease (MRD) after allogeneic transplantation, the Acute Lymphoblastic Leukemia Berlin-Frankfurt-Münster Stem Cell Transplantation Group (ALL-BFM-SCT) conducted a prospective clinical trial.Patients and MethodsIn the ALL-BFM-SCT 2003 trial, MRD was assessed in the bone marrow at days +30, +60, +90, +180, and +365 after transplantation in 113 patients with relapsed disease. Standardized quantification of MRD was performed according to the guidelines of the Euro-MRD Group.ResultsAll patients showed a 3-year probability of event-free survival (pEFS) of 55%. The cumulative incidence rates of relapse and treatment-related mortality were 32% and 12%, respectively. The pEFS was 60% for patients who received their transplantations in second complete remission, 50% for patients in ≥ third complete remission, and 0% for patients not in remission (P = .015). At all time points, the level of MRD was inversely correlated with event-free survival (EFS; P < .004) and positively correlated with the cumulative incidence of relapse (P < .01). A multivariable Cox model was fitted for each time point, which showed that MRD ≥ 10−4leukemic cells was consistently correlated with inferior EFS (P < .003). The accuracy of MRD measurements in predicting relapse was investigated with time-dependent receiver operating curves at days +30, +60, +90, and +180. From day +60 onward, the discriminatory power of MRD detection to predict the probability of relapse after 1, 3, 6, and 9 months was more than 96%, more than 87%, more than 71%, and more than 61%, respectively.ConclusionMRD after transplantation was a reliable marker for predicting impending relapses and could thus serve as the basis for pre-emptive therapy.
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer
Authors: Van Cutsem Eric , Lenz Heinz-Josef , Köhne Claus-Henning , Heinemann Volker , Tejpar Sabine , Melezínek Ivan , Beier Frank , Stroh Christopher , Rougier Philippe , van Krieken J. Han , Ciardiello Fortunato 
Published: January 2015

Purpose The phase III CRYSTAL study demonstrated that addition of cetuximab to fluorouracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival, progression-free survival, and objective response in the first-line treatment of patients with KRAS codon 12/13 (exon 2) wild-type metastatic colorectal cancer (mCRC). Outcome was reassessed in subgroups defined by extended RAS mutation testing. Patients and Methods Existing DNA samples from KRAS exon 2 wild-type tumors from CRYSTAL study patients were reanalyzed for other RAS mutations in four additional KRAS codons (exons 3 and 4) and six NRAS codons (exons 2, 3, and 4) using beads, emulsion, amplification, and magnetics technology. No tissue microdissection was performed. A ≥ 5% mutant allele cutoff was used to call mutations. Results Mutation status was evaluable in 430 (64.6%) of 666 patients with KRAS exon 2 wild-type tumors. Other RAS mutations were detected in 63 (14.7%) of 430 patients. In those with RAS wild-type tumors, a significant benefit across all efficacy end points was associated with the addition of cetuximab to FOLFIRI. In patients with other RAS tumor mutations, no difference in efficacy outcomes between treatment groups was seen. The safety profile in RAS subgroups was similar and in line with expectations. Conclusion In the first-line treatment of mCRC, patients with RAS wild-type tumors derived a significant benefit from the addition of cetuximab to FOLFIRI; patients with RAS tumor mutations did not. Molecular testing of tumors for all activating RAS mutations is essential before considering anti–epidermal growth factor receptor therapy, thereby allowing the further tailoring of cetuximab administration to maximize patient benefit.